MaxCyte Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +0.6% | -3.9% | -2.5% | -1.1% | -3.7% | -4.0% | -4.4% | -2.9% | -5.1% | -4.0% | -5.0% | |
| – | -11.3% | -6.1% | -1.7% | -1.6% | -0.7% | -9.3% | -8.0% | -13.0% | -5.0% | +3.9% | -1.4% | |
| – | -5.4% | -52.2% | +68.6% | -1.5% | -24.6% | -16.1% | -34.9% | -14.8% | +54.7% | -27.5% | +3.3% | |
| – | -11.5% | -6.4% | -0.1% | -2.2% | +0.4% | -10.5% | -8.5% | -16.5% | -2.5% | -85.9% | +626.0% | |
| – | -29.2% | +3.7% | -23.5% | -0.5% | +2.7% | +18.0% | +4.1% | +44.4% | -57.8% | +21.2% | -7.6% | |
| – | -2.4% | -2.2% | -6.7% | -6.9% | -14.2% | -7.2% | -4.1% | -4.1% | -0.8% | +1.1% | +2.2% | |
| – | – | – | – | – | – | – | -4.4% | -5.2% | – | – | – | |
| – | – | – | – | – | – | – | +28.1% | +4.5% | -2.5% | +20.5% | -2.2% | |
| – | +8.3% | -12.6% | -4.2% | +16.8% | -5.9% | -8.0% | -5.0% | +14.4% | -6.6% | -14.3% | -2.5% | |
| – | +7.2% | -24.5% | -8.9% | +43.6% | -10.5% | -19.3% | -9.3% | +39.4% | -11.4% | -28.4% | -3.1% | |
| – | +10.8% | +6.6% | +6.4% | +3.3% | -4.7% | +47.7% | +2.5% | +0.5% | +10.8% | -5.6% | +11.2% | |
| – | +66.4% | +125.3% | -43.1% | +95.7% | -27.2% | +67.8% | -46.9% | +6.3% | +8.9% | -14.6% | +45.0% | |
| – | -0.5% | -2.5% | -2.3% | -3.6% | -3.3% | -3.3% | -4.4% | -5.5% | -4.9% | -2.1% | -5.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.2% | +0.4% | +0.5% | +0.4% | -0.2% | +1.1% | +0.4% | -0.1% | +0.1% | +0.4% | 0.0% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.